
Mitigating nitrosamine risk requires assessing each product individually and chasing zero nitrite in pharmaceutical excipients is often impractical and costly.
pharmaceutical science and technology news
over 22 years ago
Spotlight on Business Riskover 22 years ago
Vibration Technology for Active Dry-Powder Inhalersover 22 years ago
In the Spotlight April 2004over 22 years ago
FDA Attacks Counterfeitsover 22 years ago
Synthetic Excipients Challenge All-Natural Organicsover 22 years ago
Controlled-Release Dosage Forms for Diltiazem Hydrochloride





